Tivdak Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of cervical cancer biology, advancements in antibody-drug conjugate platforms, regulatory approvals for targeted oncology drugs, expansion of oncology treatment centers, rising awareness of advanced cancer therapies.

The growth in the forecast period can be attributed to expansion of personalized oncology treatment pathways, increasing investments in adc research and development, growing demand for targeted therapies in solid tumors, expansion of global oncology drug access, integration of biomarker-driven treatment selection. Major trends in the forecast period include expansion of antibody-drug conjugate therapies, growing focus on targeted cervical cancer treatments, increasing adoption in second-line oncology care, rising emphasis on precision oncology approaches, enhanced patient stratification in advanced cancer care.

The rising incidence of cervical cancer is expected to support the growth of the Tivdak market in the coming years. Cervical cancer is a type of cancer that begins in the cervix, the lower portion of the uterus connecting to the vagina. The increase in cervical cancer cases is primarily driven by persistent HPV infections and limited access to screening, particularly in regions with inadequate healthcare services. Tivdak (tisotumab vedotin) is used to treat recurrent or metastatic cervical cancer by targeting Trop-2 on cancer cells and delivering a chemotherapy agent directly to destroy tumor cells. For example, in May 2024, according to the Canadian Cancer Society, a Canada-based community organization, approximately 1,600 Canadian women were projected to be diagnosed with cervical cancer in 2024, with around 400 expected to die from the disease. Therefore, the increasing incidence of cervical cancer is driving the growth of the Tivdak market.

A key trend in the Tivdak market is obtaining regulatory approvals to expand its use across various cancer types, increasing market penetration and potential revenue. Regulatory approvals refer to the official authorization from health authorities that allows a drug to be marketed and used for medical purposes after demonstrating safety, efficacy, and quality. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical company, in collaboration with Genmab, a Denmark-based biotechnology company, received full approval for Tivdak (tisotumab vedotin-tftv) to treat patients with recurrent or metastatic cervical cancer who have progressed after chemotherapy. This approval is significant as Tivdak became the first antibody-drug conjugate to demonstrate improved overall survival in this patient group, with a median survival of 11.5 months compared to 9.5 months for chemotherapy. The decision followed positive outcomes from the Phase 3 innovaTV 301 study and reflects Tivdak’s manageable safety profile, which includes common side effects such as decreased hemoglobin levels and peripheral neuropathy.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for an undisclosed amount. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by incorporating advanced antibody-drug conjugate technology, expanding its pipeline to 60 programs, and positioning itself as a leader in cancer therapies, with significant revenue expected by 2030. Seagen Inc., a US-based biotechnology company, develops Tivdak (tisotumab vedotin-tftv) and provides support for patients and caregivers.

Major companies operating in the tivdak market are Genmab A/S, Pfizer Inc.

North America was the largest region in the tivdak market in 2025. The regions covered in the tivdak market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tivdak market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the tivdak market by increasing costs of imported cytotoxic payloads, antibody components, sterile manufacturing equipment, and temperature-controlled distribution systems. Oncology markets in North America and Europe are most affected due to reliance on global adc supply chains and specialized imports. These tariffs are increasing overall therapy costs and influencing hospital procurement decisions. However, they are also encouraging domestic adc manufacturing, localized fill-finish operations, and long-term investments in regional oncology drug production infrastructure.

The tivdak market research report is one of a series of new reports that provides tivdak market statistics, including tivdak industry global market size, regional shares, competitors with a tivdak market share, detailed tivdak market segments, market trends and opportunities, and any further data you may need to thrive in the tivdak industry. This tivdak market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tivdak (tisotumab vedotin-tftv) is a prescription drug used to treat adults with cervical cancer that has recurred or metastasized. It is specifically indicated for patients whose disease has progressed during or following chemotherapy.

The primary clinical indications for Tivdak include recurrent or metastatic cervical cancer, second-line therapy in cervical cancer, and exploratory off-label uses. Recurrent or metastatic cervical cancer refers to the return of cancer or its spread to other parts of the body after initial treatment. Tivdak can be administered orally or parenterally and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It serves end users such as hospitals, home care settings, and specialty clinics.

The tivdak market consists of sales of tivdak vials, sterile syringes and needles, IV infusion bags, infusion sets, and sterile water for injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.